Z01 CP010201 - 10571 (ZIA) | |||
---|---|---|---|
Title | LTG_Prokunina | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Prokunina, Liudmilla | NCI Program Director | PARK |
Cancer Activity | Training | Division | DCEG |
Funded Amount | $508,956 | Project Dates | 10/12/2010 - 00/00/0000 |
Fiscal Year | 2015 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Bladder (30.0%) Breast (10.0%) Liver Cancer (30.0%) Prostate (30.0%) |
||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Endogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
Recent genome-wide association studies (GWAS) have identified multiple common inherited genetic susceptibility factors that may play a role in a variety of human diseases and outcomes. The primary goal of my research is to identify the functional links between these genetic associations and molecular phenotypes. We use a wide range of methods including DNA sequencing and genotyping, RNA sequencing, statistical imputation, protein expression studies, DNA-protein interaction analysis, cell culture, and epigenetic studies to identify relevant functional mechanisms that may account for cancer susceptibility. My laboratory has several lines of investigation. The first line of my work is on post-GWAS follow-up studies on bladder cancer. Of 11 GWAS susceptibility regions identified for bladder cancer, we worked through and published conclusiove results on 3 regions - UGT1A cluster at 2q37, PSCA gene at 8q24.2 and SLC14A21 region at 18q12.3. Additional papers on other bladder cancer GWAS regions are in preparation. The second line of my research is on genetics of cancer and immunity. Previsouly, we explored the role of alternative splicing in the OCLN gene in permissiveness or resistance to HCV infection. Recently, we have identified a novel human interferon, IFN-lambda 4, which is created by a genetic variant strongly associated with outcome of HCV infection and treatment (clearance or non-clearance). We are exploring this gene and its genetic variants and several protein isoforms in relation to infections and cancer. |